Prudential Financial’s Vanda Pharmaceuticals VNDA Stock Holding History

Prudential Financial’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-449,403	Closed	-$2.24M	–	2452
2025 Q3	$2.24M	Sell	449,403 -156,600	-26%	-$725K	﹤0.01%	1294
2025 Q2	$2.86M	Sell	606,003 -104,707	-15%	-$458K	﹤0.01%	1212
2025 Q1	$3.26M	Sell	710,710 -64,270	-8%	-$300K	﹤0.01%	1043
2024 Q4	$3.71M	Sell	774,980 -1,800	-0.2%	-$8.64K	0.01%	995
2024 Q3	$3.64M	Sell	776,780 -300	-0%	-$1.61K	0.01%	1145
2024 Q2	$4.39M	Sell	777,080 -321,400	-29%	-$1.66M	0.01%	985
2024 Q1	$4.51M	Sell	1,098,480 -439,300	-29%	-$1.76M	0.01%	978
2023 Q4	$6.49M	Buy	1,537,780 +55,000	+4%	+$222K	0.01%	822
2023 Q3	$6.41M	Buy	1,482,780 +308,010	+26%	+$1.71M	0.01%	806
2023 Q2	$7.74M	Buy	1,174,770 +110,861	+10%	+$711K	0.01%	741
2023 Q1	$7.22M	Buy	1,063,909 +267,750	+34%	+$1.88M	0.01%	750
2022 Q4	$5.88M	Buy	796,159 +114,930	+17%	+$1.12M	0.01%	801
2022 Q3	$6.73M	Buy	681,229 +157,750	+30%	+$1.67M	0.01%	782
2022 Q2	$5.71M	Buy	523,479 +12,775	+3%	+$132K	0.01%	845
2022 Q1	$5.78M	Sell	510,704 -8,850	-2%	-$116K	0.01%	914
2021 Q4	$8.15M	Sell	519,554 -127,201	-20%	-$2.22M	0.01%	789
2021 Q3	$11.1M	Sell	646,755 -124,357	-16%	-$2.18M	0.02%	699
2021 Q2	$16.6M	Sell	771,112 -106,234	-12%	-$1.9M	0.02%	579
2021 Q1	$13.2M	Sell	877,346 -151,130	-15%	-$2.45M	0.02%	653
2020 Q4	$13.5M	Sell	1,028,476 -6,977	-0.7%	-$84K	0.02%	614
2020 Q3	$10M	Sell	1,035,453 -315,160	-23%	-$3.37M	0.02%	652
2020 Q2	$15.5M	Buy	1,350,613 +74,702	+6%	+$846K	0.03%	529
2020 Q1	$13.2M	Buy	1,275,911 +10,214	+0.8%	+$127K	0.03%	533
2019 Q4	$20.8M	Buy	1,265,697 +311,797	+33%	+$4.71M	0.03%	576
2019 Q3	$12.7M	Buy	953,900 +602,359	+171%	+$8.39M	0.02%	710
2019 Q2	$4.95M	Buy	351,541 +6,690	+2%	+$106K	0.01%	1167
2019 Q1	$6.34M	Sell	344,851 -326,655	-49%	-$7.44M	0.01%	1030
2018 Q4	$17.5M	Sell	671,506 -121,996	-15%	-$2.87M	0.03%	589
2018 Q3	$18.2M	Sell	793,502 -36,737	-4%	-$750K	0.03%	654
2018 Q2	$15.8M	Sell	830,239 -17,540	-2%	-$293K	0.02%	742
2018 Q1	$14.3M	Buy	847,779 +143,770	+20%	+$2.41M	0.02%	747
2017 Q4	$10.7M	Buy	704,009 +115,031	+20%	+$1.71M	0.01%	886
2017 Q3	$10.5M	Buy	588,978 +7,490	+1%	+$125K	0.02%	870
2017 Q2	$9.48M	Sell	581,488 -32,830	-5%	-$473K	0.01%	901
2017 Q1	$8.6M	Buy	614,318 +4,700	+0.8%	+$67K	0.01%	920
2016 Q4	$9.72M	Buy	609,618 +11,100	+2%	+$178K	0.02%	864
2016 Q3	$9.96M	Buy	598,518 +244,410	+69%	+$3.29M	0.02%	830
2016 Q2	$3.96M	Buy	+354,108	New	+$3.43M	0.01%	1233
2014 Q3	–	Sell	-47,677	Closed	-$771K	–	2313
2014 Q2	$771K	Buy	47,677 +3,769	+9%	+$50.2K	﹤0.01%	1893
2014 Q1	$714K	Buy	43,908 +100	+0.2%	+$1.42K	﹤0.01%	1863
2013 Q4	$544K	Sell	43,808 -42,500	-49%	-$427K	﹤0.01%	1948
2013 Q3	$947K	Buy	86,308 +21,300	+33%	+$228K	﹤0.01%	1756
2013 Q2	$525K	Buy	+65,008	New	+$438K	﹤0.01%	1929

Other funds holding VNDA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

Prudential Financial's VNDA Position: Q4 2025 in Review

Prudential Financial sold out of Vanda Pharmaceuticals (VNDA) in Q4 2025, closing a stake of 449,403 shares — an estimated $2.24M sold.

Prudential Financial first reported a position in VNDA in Q2 2013 and held it in 43 quarters. The position peaked at $20.8M in Q4 2019. 153 funds tracked by Wall St. Rank hold VNDA as of Q4 2025.

Prudential Financial reported no remaining Vanda Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Prudential Financial sold 449,403 Vanda Pharmaceuticals shares in Q4 2025, an estimated $2.24M.
Prudential Financial first reported a position in Vanda Pharmaceuticals in Q2 2013 and held it in 43 quarters.
Prudential Financial's Vanda Pharmaceuticals position peaked at $20.8M in Q4 2019.
153 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q4 2025.

Based on Prudential Financial's 13F filing for Q4 2025, filed 13 Feb 2026.